{"entity":{"id":"nct02263508","kind":"trial","name":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","aka":["MASTERKEY-265"],"tldr":"A phase 3 trial of Talimogene laherparepvec and Pembrolizumab in Melanoma, run by Amgen, recorded as terminated on the registry.","summary":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma is a phase 3 interventional study registered as NCT02263508 by Amgen, with 713 participants recorded, started 2014-12-08 and due to reach its primary completion in 2021-03-11. Interventions recorded: Talimogene Laherparepvec, Pembrolizumab, Placebo. Conditions recorded: Melanoma.\n\nLinked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02263508","url":"https://clinicaltrials.gov/study/NCT02263508"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","advanced-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["talimogene-laherparepvec","pembrolizumab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02263508","phase":"3","setting":"A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)","sponsor":"Amgen","started":"2014-12-08","startedType":"actual","yearReported":2022,"enrolled":713,"enrolledBasis":"registry","outcomes":[{"endpoint":"Phase 3: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessed Using Modified RECIST 1.1","primary":true,"unit":"months","arms":[{"name":"Phase 3: Placebo + Pembrolizumab","n":346,"value":8.5,"note":"95% CI 5.72 to 13.54; Figures from the ClinicalTrials.gov results section (first posted 2022-05-16), not from a publication"},{"name":"Phase 3: Talimogene Laherparepvec + Pembrolizumab","n":346,"value":14.3,"note":"95% CI 10.25 to 22.11"}],"hr":0.86,"ci":[0.71,1.04],"p":"0.13","source":"https://clinicaltrials.gov/study/NCT02263508?tab=results"},{"endpoint":"Phase 1b: Objective Response Rate (ORR)","unit":"%","arms":[{"name":"Phase 1b: Talimogene Laherparepvec + Pembrolizumab","n":21,"value":61.9,"note":"95% CI 38.4 to 81.9; Figures from the ClinicalTrials.gov results section (first posted 2022-05-16), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT02263508?tab=results"}]},"route":"/trials/nct02263508/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}